Stockreport

NHS England to offer Daiichi Sankyo's quizartinib for AML [Yahoo! Finance]

DAIICHI SANKYO S/ADR  (DSNKY) 
PDF Daiichi Sankyo's quizartinib for acute myeloid leukaemia (AML) patients with the FLT3-ITD mutation. The decision, facilitated by the Cancer Drugs Fund, will enable imm [Read more]